Skip to main
CLDX

Celldex Therapeutics (CLDX) Stock Forecast & Price Target

Celldex Therapeutics (CLDX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Celldex Therapeutics is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. With a promising pipeline and a single operating/segment reporting structure, the company appears to be in a strong financial position for growth, with an estimated peak global sales of $3 billion for their lead candidate barzolvolimab. Their focus on mast cell-driven indications has resulted in a differentiated status and promising data showcasing the role of mast cells in various conditions, such as chronic spontaneous urticaria (CSU). Their upcoming Phase 3 readout for CSU, expected in October 2026, has the potential to be a game changer for the company and could lead to front-line usage. With a high conviction and a reiteration of a Buy rating, we see Celldex Therapeutics as a leader in the mast cell space and a top pick for 2026.

Bears say

Celldex Therapeutics is facing challenges as their recent Phase 2 trial of barzolvolimab in prurigo nodularis (PN) failed to meet primary and secondary endpoints, leading to program discontinuation. Furthermore, their potential in chronic spontaneous urticaria (CSU) has been questioned as recent research suggests that mast cells might not be the main driver for the disease, and it is uncertain if the subcutaneous form of barzolvolimab would be as effective as the intravenous form. The company's cash flows are projected to 2035E, and a price target of $61/share has been determined using a probability-adjusted DCF analysis, but the overall clinical trial risk for the company remains high.

Celldex Therapeutics (CLDX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celldex Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celldex Therapeutics (CLDX) Forecast

Analysts have given Celldex Therapeutics (CLDX) a Buy based on their latest research and market trends.

According to 11 analysts, Celldex Therapeutics (CLDX) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celldex Therapeutics (CLDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.